Our Cyprotex site in the USA is growing!
As part of its expansion plans, Cyprotex US, LLC, is relocating from its site in Watertown to a new facility in Framingham, Massachusetts. The new site, located around 30km west of Boston, is easily accessible with dedicated parking and good transport links.
The new state-of-the-art laboratory and office space at Framingham covers approximately 30,000 sq ft, allowing Cyprotex’s US ADME-Tox services business to grow by around 3-fold. The company has also invested heavily in the latest liquid handling automation and mass spectrometers enabling Cyprotex to have one of the shortest turnarounds in the industry and the capacity for large scale screening projects. These have attracted several new partnerships with medium and large Pharma companies which have fuelled the expansion of the business. Our specialist technologies draw interest from a range of different industries and we continue our cutting edge research in areas such as transcriptomics, 3D cell-based models and microelectrode array for predicting drug-induced toxicity.
Contact us to arrange a tour of our new facility
In December 2016, Cyprotex was acquired by Evotec (www.evotec.com).
The acquisition is beneficial for both parties, and the individual capabilities and expertise of the two companies are highly synergistic.
Cyprotex’s customers will now be able to access Evotec’s integrated and standalone drug discovery services and the acquisition expands Cyprotex’s service portfolio to include medicinal chemistry, structural biology and in vitro and in vivo pharmacology services. Evotec can also offer specialist expertise in key therapeutic areas such as neuroscience, pain, metabolic diseases, oncology, respiratory and inflammation.
Evotec’s customers will benefit from Cyprotex’s world leading in vitro and in silico ADME-Tox expertise and will gain access to an extensive portfolio of services and proprietary techniques.
Apart from the obvious advantages to our customers from the combined expertise and expanded capabilities, very little will change in terms of our processes and customer interactions. We are fully committed to maintaining and building on our relationship with our customers and will continue to deliver a high quality reliable service.
If you have any questions or concerns then we will be happy to address them. Please contact us on CyprotexEnquiries@evotec.eu
Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683